Team lead in the manufacturing and QC of diverse, in-house research-grade rAAV vectors for in vitro and in vivo research studies. Supervision of the upstream and downstream processing of small- to medium-scale research-grade batches of rAAV vectors using multiple production systems and oversight of in-process testing and process development, as well as QC. Development of new production methods and extensive interaction with the research-stage program teams. Management of the production schedule and capacities to meet vector needs for both programs and novel capsid discovery work. Authorship of protocols, reports, operating procedures, and other documents.

Develop and expand infrastructure to produce clinical grade HSV-1 based oncolytics.

I work in the genetic perturbation platform to answer fundamental biologic questions based on gene editing technology. My focus is on creating efficient delivery mechanisms for CRISPR/Cas9 into a wide variety of tissues.

Responsible for the development of upstream processes and cell line engineering for clinical grade viral based gene therapy agents.

Investigation of the contribution of SUMO biology to PI3K/Erk/Akt signaling in the context of cancer

Research involving the host cell dynamics during the early stages of HSV-1 infection. Proteomic analysis of human based cells reveals widespread changes in protein modifications during HSV-1 infection. Investigation of contributions of the SUMO conjugation network with respect to restriction to HSV-1 infection.

Production and Purification of Highly Replication Defective HSV-1 Based Gene Therapy Vectors

Investigation of optimal cryopreservation of primary cell lines

Free energy algorithm evaluation for molecular modeling of ligand receptor docking

Development of on line in situ monitoring system for solvent exchanges through near infrared spectroscopy.